947739-49-3Relevant academic research and scientific papers
Orally available and efficacious α4β1/α4β7 integrin inhibitors
Xu, Ying-Zi,Smith, Jenifer L.,Semko, Christopher M.,Rossiter, Kassandra I.,Fukuda, Juri Y.,Dappen, Michael S.,Quincy, David A.,Konradi, Andrei W.,Mao, Wenxian,Welch, Brent,Dreyer, Mark L.,Samant, Bhushan,Zhang, Hongbin,Lugar, Judevin,Liao, Zhenmei,Henschel, Carrol,Petersen, Eric,Vandevert, Christopher,Shoemaker, Mark,Wehner, Nancy,Mutter, Linda,Shopp, George,Krimm, Michael,Chen, Linda,Wipke, Brian,Dofiles, Lilibeth,Gallager, Ian,Sauer, John-Michael,Messersmith, Elizabeth K.,Pleiss, Michael A.,Bard, Frederique,Yednock, Ted A.
, p. 4370 - 4373 (2013/07/26)
A series of potent α4β1/α4β7 integrin inhibitors is reported, including an inhibitor 12d with remarkable oral exposure and efficacy in rat models of rheumatoid arthritis and Crohn's disease.
PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
-
, (2008/06/13)
Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and. in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subjec
